OM
STRO icon

Opaleye Management’s Sutro Biopharma STRO Stock Holding History

Opaleye Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75M Hold
190,671
– – 0.63% 32
2025
Q4 		$2.21M Buy
+190,671
New +$1.81M 0.29% 44
2024
Q1 		– Sell
-30,149
Closed -$1.29M – 58
2023
Q4 		$1.29M Buy
+30,149
New +$957K 0.34% 42
2023
Q3 		– Sell
-30,700
Closed -$1.43M – 50
2023
Q2 		$1.43M Buy
+30,700
New +$1.53M 0.34% 38
2022
Q2 		– Sell
-8,998
Closed -$740K – 54
2022
Q1 		$740K Sell
8,998
-59,002
-87% -$5.61M 0.23% 43
2021
Q4 		$10.1M Buy
68,000
+14,220
+26% +$2.55M 2.15% 16
2021
Q3 		$10.2M Buy
53,780
+4,090
+8% +$778K 1.9% 16
2021
Q2 		$9.24M Buy
49,690
+15,495
+45% +$3.03M 1.53% 22
2021
Q1 		$7.78M Buy
34,195
+1,975
+6% +$469K 1.14% 27
2020
Q4 		$7M Buy
32,220
+17,620
+121% +$2.92M 0.91% 29
2020
Q3 		$1.47M Buy
+14,600
New +$1.38M 0.29% 46

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Opaleye Management's STRO Position: Q1 2026 in Review

Opaleye Management held its Sutro Biopharma (STRO) position steady in Q1 2026 at 190,671 shares worth $4.75M. The position accounts for 0.63% of the portfolio, ranked #32.

Opaleye Management first reported a position in STRO in Q3 2020 and has held it in 11 quarters since. The position peaked at $10.2M in Q3 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Opaleye Management held 190,671 shares of Sutro Biopharma worth $4.75M as of Q1 2026.
  • Opaleye Management left its Sutro Biopharma share count unchanged in Q1 2026.
  • Sutro Biopharma made up 0.63% of Opaleye Management's portfolio in Q1 2026, its #32 holding.
  • Opaleye Management first reported a position in Sutro Biopharma in Q3 2020 and has held it in 11 quarters since.
  • Opaleye Management's Sutro Biopharma position peaked at $10.2M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.